ERBB2 and breast cancer: Furthermore, we explored the RFS in comparison with the complete pathological response (CPR for all BC subtypes that received any chemotherapy (Taxane, FAC, Ixabepilone, Anthracycline, FEC, or CMF), any endocrine therapy, or any anti-HER2 therapy (Figure 5c–h).